RNA-LNP Process Development & Platform Innovation Lead

Eli Lilly and Company; Boston (MA); On-site; USD 168,000 - 268,000; Full time

Benefits offered by this job

401(k) plan

Pension

Vacation benefits

Health benefits

Flexible benefits

Life insurance

Well-being programs

Job summary

Lilly’s Advanced Delivery Systems team in Boston seeks a PhD-level scientist to drive RNA-LNP platform innovation and scale-up processes for nonviral delivery vehicles. The role emphasizes mechanistic process understanding, collaboration, and successful tech transfers supporting clinical manufacturing.

You will work across discovery and development, mentoring junior scientists, and ensuring regulatory readiness while advancing portfolio assets for early-phase clinical manufacture in a dynamic,

Qualifications

• Ph.D. in a related field as listed.
• Experience with RNA-LNP formulations and nonviral delivery.
• Ability to mentor junior scientists and collaborate across teams.

Responsibilities

• Drive RNA-LNP platform innovation through publications and industry engagement.
• Develop mechanistic understanding of RNA-LNP unit operations and SOPs.
• Build process capabilities from lab to scale-up for GMP readiness.
• Support tech transfers to internal and external manufacturing sites and manage regulatory readiness.

Skills

RNA-LNP formulations

Process development

Tech transfer

Analytical characterization

Statistical analysis

Publications

Cross-team collaboration

Education

Ph.D. in Chemical Engineering, Biomedical Engineering, Chemistry, Pharmaceutical Sciences, or related field

Tools

DLS

SAXS

Cryo-TEM

SEC

HPLC

AF4

Job description

Lilly’s Advanced Delivery Systems team in Boston seeks a PhD-level scientist to drive RNA-LNP platform innovation and scale-up processes for nonviral delivery vehicles. The role emphasizes mechanistic process understanding, collaboration, and successful tech transfers supporting clinical manufacturing.

You will work across discovery and development, mentoring junior scientists, and ensuring regulatory readiness while advancing portfolio assets for early-phase clinical manufacture in a dynamic,